Stories

Knight Cancer Institute patient care programs earn renewed accreditation with full commendation

October 15, 2012

The Knight Cancer Institute at Oregon Health & Science University (OHSU) received a three-year accreditation with full commendation from the American College of Surgeons’ Commission on Cancer following its recent 2012 evaluation. That level of ...

Knight Cancer Institute deputy director selected for prostate cancer Dream Team

October 09, 2012

Tomasz Beer, M.D., deputy director of the Knight Cancer Institute at Oregon Health & Science University (OHSU), was selected as one of six top scientists to take part in a research Dream Team that joins together world-class institutions to study ...

OHSU Knight Cancer Institute recruits leader-elect of international clinical trial cooperative group

July 31, 2012

Charles D. Blanke, M.D., chair-elect to one of the U.S. National Cancer Institute’s five large-scale cooperative groups that test new cancer treatments and prevention programs, will join the Knight Cancer Institute at Oregon Health & Science ...

OHSU Knight Cancer Institute recruits leader-elect of international clinical trial cooperative group

July 31, 2012

Charles D. Blanke, M.D., chair-elect to one of the U.S. National Cancer Institute’s five large-scale cooperative groups that test new cancer treatments and prevention programs, will join the Knight Cancer Institute at Oregon Health & Science ...

Lenalidomide significantly prolongs disease control for multiple myeloma patients following stem cell transplantation

May 15, 2012

Multiple myeloma patients are better equipped to halt progression of this blood cancer if treated with lenalidomide, or Revlimid®, following a stem cell transplant, according to a study co-authored by a physician with the Oregon Health & Science ...

Lenalidomide significantly prolongs disease control for multiple myeloma patients following stem cell transplantation

May 15, 2012

Multiple myeloma patients are better equipped to halt progression of this blood cancer if treated with lenalidomide, or Revlimid®, following a stem cell transplant, according to a study co-authored by a physician with the Oregon Health & Science ...

Two risk factors may be most relevant in determining when to start regular breast cancer screening

April 30, 2012

A family history of breast cancer and dense breast tissue each increase the risk of breast cancer by at least twofold for women in their 40s, according to a study led by an Oregon Health & Science University (OHSU) researcher. The importance of these ...

Two risk factors may be most relevant in determining when to start regular breast cancer screening

April 30, 2012

A family history of breast cancer and dense breast tissue each increase the risk of breast cancer by at least twofold for women in their 40s, according to a study led by an Oregon Health & Science University (OHSU) researcher. The importance of these ...

OHSU Knight Cancer Institute to provide free head, neck cancer screenings

April 17, 2012

Calendar Alert WHAT Oregon Health & Science University Knight Cancer Institute is offering free screenings for cancers that develop on the skin (face and scalp) as well as in the mouth, throat and neck. Health care professionals will also provide ...

OHSU Doernbecher cancer survivor meets lifesaving bone marrow donor

April 10, 2012

WHAT OHSU Doernbecher patient and cancer survivor Stella Monteverde-Cakebread, 10, will meet the man who saved her life at a celebration designed to thank friends and community members, and to encourage more ethnic minorities to participate in the Be ...

Stories

OHSU in the News